NCT03943082 is a NA clinical trial of Cancer Educational Materials in Malignant Neoplasm, sponsored by University of California, San Francisco.

Who is sponsoring NCT03943082?

NCT03943082 is sponsored by University of California, San Francisco.

What drugs are being tested in NCT03943082?

Interventions in NCT03943082: Cancer Educational Materials, Follow-Up Care, Questionnaire.

What condition does NCT03943082 study?

NCT03943082 studies Malignant Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm.

Is NCT03943082 still recruiting?

NCT03943082 is currently terminated. Last updated 16 November 2021.

Last reviewed 2021-11-16 · How we verify

NCT03943082

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Phone Call About Financial Reimbursement Program on Access to Cancer Clinical Trials

Terminated NA Last updated 16 November 2021

What this trial tests

NA trial testing Cancer Educational Materials in Malignant Neoplasm in 252 participants. Terminated before completion.

Timeline

8 April 2019

Primary endpoint
26 October 2021

26 October 2021

Quick facts

Lead sponsor	University of California, San Francisco
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	health services research
Enrollment	252
Start date	8 April 2019
Primary completion	26 October 2021
Estimated completion	26 October 2021
Sites	2 locations across United States

Drugs / interventions tested

Cancer Educational Materials
Follow-Up Care
Questionnaire

Conditions studied

Malignant Neoplasm — all drugs for Malignant Neoplasm →
Hematopoietic and Lymphoid Cell Neoplasm — all drugs for Hematopoietic and Lymphoid Cell Neoplasm →

Sponsor

University of California, San Francisco

Who can join

7 and older, any sex, with Malignant Neoplasm or Hematopoietic and Lymphoid Cell Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial studies how well a follow-up phone call regarding financial reimbursement program (FRP) works in improving cancer patients' access to therapeutic cancer clinical trials. Follow-up phone call intervention regarding FRP may improve recruitment of cancer patients to cancer therapeutic clinical trials.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Implementation of a Multisite Financial Reimbursement Program in Cancer Clinical Trials Integrated With Patient Navigation: A Pilot Randomized Clinical Trial.
Borno HT, Zhang L, Zhang S, Lin TK, et al · · 2022 · cited 15× · PMID 35196064 · DOI 10.1200/op.21.00328

Verify or expand the search:

Other trials of Cancer Educational Materials

Trials testing the same drug.

NCT04496739 — Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE) · NA · active not recruiting
NCT05011799 — The Peer Genetic Study · NA · completed
NCT03929926 — Proactive Outreach and Shared Decision Making in Improving Lung Cancer Screening Rates in Primary Care Patients · NA · completed

Other recruiting trials for Malignant Neoplasm

Currently open trials in the same condition.

NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
NCT07252739 — KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) · Phase 2 · recruiting
NCT07247110 — A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001) · Phase 1 · recruiting
NCT07131007 — Construction and Evaluation of Tumor Immunotherapy and Organ Damage Early Warning System Based on Multi-omics · recruiting

Other University of California, San Francisco trials

Trials by the same sponsor.

NCT05284773 — Screening for Acute Malnutrition · NA · withdrawn
NCT04634851 — Video Home Visits for Dietary Counselling · NA · not yet recruiting
NCT06065670 — Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a M · Phase 1, PHASE2 · not yet recruiting
NCT07534098 — Intervention for Hearing Health Among Native Americans · NA · not yet recruiting
NCT06960421 — Exercise-based Frailty Intervention in Lung Transplantation (XFIT) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03943082 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, San Francisco
Last refreshed: 16 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03943082.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing